Integrated Animal Health Inks Distributor Agreement with SIA Baltic Zoolife Ltd.

Includes exclusive distribution of IAH product technologies in Baltic States and Belarus

LAWRENCE, Kan., Nov. 12, 2015 – Integrated Animal Health, LLC (IAH), a global company focused on identifying and commercializing new-to-the-world animal health solutions, expands distribution of its innovative products in Northern Europe to Latvia, Lithuania, Estonia and Belarus. This agreement marks the second distribution agreement in two months, and third this year as IAH continues to build international momentum for its commercial technologies for large and small animals.

"Agreements with strong, specialized companies in the industry, such as Baltic Zoolife, are critical to our global expansion," says Laszlo Kiss, D.V.M., M.B.A., IAH European director. "Baltic Zoolife has established itself as a key channel partner in this region. We are delighted to work with them as we continue to grow our presence in Europe with our pioneering (new and existing) technologies for livestock and companion pets."

"In recent years, the agricultural industry in Belarus and the Baltic countries has seen significant growth, which has led to the development of modern, state-of-the-art farming operations equipped with advanced technologies," says Victoria Podberezina, SIA Baltic Zoolife founder and board chairman. "Through this exciting expansion, local farmers will have access to IAH's innovative, high quality products to help strengthen the farming sector and accelerate productivity in the region."

A range of IAH product technologies for large and small animals will be distributed by SIA Baltic Zoolife.

"What I hear time and time again in this industry, is the importance of animal health and nutrition. Farmers show immense interest in food supplements, minerals, milk equivalents and antibiotic-free products. The well-being of the livestock in this region is an essential element that is required for the farming sector to continue to thrive," adds Ms. Podberezina.

"Similar to other major economies of the world, consumer demand across the European Union is driving the need for improved standards for animal care and food production, including the use of fewer antibiotics," says Blake Hawley, D.V.M., M.B.A., IAH president and chief executive officer. "We are pleased to partner with SIA Baltic Zoolife to support the region's leading-edge production practices, and look forward to continuing to expand our product technologies in this region to support the health and welfare of large and small animals."

About Integrated Animal Health
Integrated Animal Health (IAH) provides multiple pathways to market for products that aim to disrupt current paradigms for the use of antibiotics, pesticides and novel animal drugs, biologics and cancer therapies used in animals. With world headquarters in the heart of the Animal Health Corridor, IAH is the new engine driving innovation in animal health by helping companies bring transformative solutions to market. Its technologies target significant and costly issues in production animal systems, such as mastitis, scours and fly control to help companies satisfy consumer demand for sustainable, natural and antibiotic-free products while meeting the demand for growth. Offering a deep and fertile pipeline of more than 30 pioneering technology platforms, IAH is advancing its pipeline to include a wide range of applications, including products targeting equine and companion animal markets. The company has offices at the Bioscience and Technology Business Center in Lawrence, Kan., as well as in Australia, Europe and New Zealand. For more information, visit iahglobal.com.

# # #

 

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…